10-Q: Bone Biologics Q1 2026: Reduced R&D Spending, Cash Burn Continues

Bone Biologics Corporation reported a net loss of $765,988 for Q1 2026, with a significant decrease in research and development expenses, while general and administrative costs rose.

Summary

• Bone Biologics Corporation filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $765,988 for the first quarter of 2026, compared to a net loss of $1,017,092 for the same period in 2025.
• Total operating expenses decreased by 22.48% to $805,054 in Q1 2026 from $1,038,486 in Q1 2025.
• Research and development expenses significantly decreased by 66.57% to $141,597 in Q1 2026 from $423,576 in Q1 2025, attributed to the timing of clinical trials.
• General and administrative expenses increased by 7.89% to $663,457 in Q1 2026 from $614,910 in Q1 2025.
• The company had $4,530,040 in cash as of March 31, 2026, which is expected to fund operations into the fourth quarter of 2026.
• The company continues to face substantial doubt regarding its ability to continue as a going concern within one year.
• No shares were sold through the At The Market (ATM) Offering Facility during the first quarter of 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the persistent going concern doubt, limited cash runway, and lack of capital raised in the quarter, despite a reduction in net loss and R&D expenses.

Positives

• Net loss decreased by 24.69% to $765,988 in Q1 2026 compared to $1,017,092 in Q1 2025.
• Total operating expenses decreased by 22.48% to $805,054 in Q1 2026.
• Interest income increased by 93.63% to $38,801 in Q1 2026 compared to $20,039 in Q1 2025.
• The company has $4.53 million in cash, expected to cover operations through Q4 2026.

Negatives

• The company incurred a net loss of $765,988 in Q1 2026.
• The company used $804,282 in cash from operating activities in Q1 2026.
• There is substantial doubt about the company's ability to continue as a going concern.
• No shares were sold through the ATM facility in Q1 2026, indicating no new capital raised through this channel during the period.
• General and administrative expenses increased by 7.89% to $663,457 in Q1 2026.

Risks

• The company's ability to raise additional capital through debt or equity financing is uncertain and may be dilutive or restrictive.
• If cash resources are insufficient, the company may need to scale back or discontinue product development programs.
• Clinical trials may encounter problems that cause delays or suspension.
• There is no assurance that patents will be approved, maintained, or provide competitive advantages.
• The company is subject to extensive regulation by governmental authorities, including the FDA, for its device/drug combination product.
• Macroeconomic factors such as inflation, rising interest rates, and potential recession add uncertainty to financing availability and operations.
• Reliance on third-party manufacturers for drug products.
• Market acceptance of products is not guaranteed.
• Dependence on licenses for certain products.

Future Outlook

The company anticipates continued substantial investment in development activities for NELL-1 as it prepares for its pivotal clinical study. Operating expenditures for the next twelve months are estimated at $5.4 million. The company expects its available cash to fund operations into the fourth quarter of 2026 and will continue to seek additional debt and/or equity financing.

Management Comments

• "We anticipate continued substantial investment in development activities for NELL-1 as we prepare for our pivotal clinical study in the future."
• "Operating expenditures for the next twelve months are estimated at $5.4 million."
• "We will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital."

Industry Context

StockSavvy.ai notes that Bone Biologics operates in the highly competitive and capital-intensive medical device sector, specifically focusing on bone regeneration. The company's reliance on clinical trial progression and FDA approval for its NELL-1/DBM product places it in a high-risk, high-reward category, typical of early-stage biotechnology firms.

Comparison to Industry Standards

• Companies in the regenerative medicine and orthopedic device space often face long development cycles and significant regulatory hurdles, similar to Bone Biologics' path with NELL-1/DBM.
• The cash burn rate of $0.8 million per quarter is within the range for clinical-stage biotech companies, but the limited cash runway into Q4 2026 highlights the critical need for future financing.
• The decrease in R&D spending, while potentially a cost-saving measure, could also indicate a shift in trial timing or a strategic pause, which needs careful monitoring against industry norms for advancing drug candidates.

Legal Proceedings

• The company is not presently a party to any legal proceedings that would have a material adverse effect on its business, results of operations, financial condition, or cash flows.

Stakeholder Impact

• Shareholders may face dilution if future equity financing is pursued.
• Creditors and suppliers may be concerned about the company's going concern status and ability to meet future obligations.
• Employees may be concerned about job security given the company's financial situation and potential need to scale back operations.

Next Steps

• Continue development activities for NELL-1/DBM.
• Prepare for a pivotal clinical study in the United States.
• Attempt to raise additional debt and/or equity financing.
• Continue to monitor cash resources and operational expenditures.

Key Dates

Recommendation

Keywords

Bone Biologics, Form 10-Q, Quarterly Report, NELL-1, DBM, Bone Regeneration, Spinal Fusion, Clinical Trials, FDA, Medical Device, Biotechnology, Biologics, Biomaterials, Orthopedics, Financial Statements, Net Loss, Cash Flow, Going Concern